Revenue Showdown: Dr. Reddy's Laboratories Limited vs Ionis Pharmaceuticals, Inc.

Pharma Giants' Revenue Battle: Dr. Reddy's vs. Ionis

__timestampDr. Reddy's Laboratories LimitedIonis Pharmaceuticals, Inc.
Wednesday, January 1, 2014132170000000214161000
Thursday, January 1, 2015148189000000283703000
Friday, January 1, 2016154708000000346620000
Sunday, January 1, 2017140809000000507666000
Monday, January 1, 2018142028000000599674000
Tuesday, January 1, 20191538510000001123000000
Wednesday, January 1, 2020174600000000729000000
Friday, January 1, 2021189722000000810000000
Saturday, January 1, 2022214391000000587000000
Sunday, January 1, 2023245879000000787647000
Monday, January 1, 2024279164000000705138000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Dr. Reddy's vs. Ionis

In the ever-evolving landscape of pharmaceuticals, Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc. have carved distinct paths. Over the past decade, Dr. Reddy's has consistently outpaced Ionis in revenue, showcasing a robust growth trajectory. From 2014 to 2023, Dr. Reddy's revenue surged by over 110%, reaching a peak in 2023. In contrast, Ionis, while showing growth, has experienced more fluctuations, with its revenue peaking in 2019 and then stabilizing.

Dr. Reddy's dominance is evident, with its 2023 revenue being approximately 300 times that of Ionis. This disparity highlights the different scales and market strategies of these companies. While Dr. Reddy's focuses on a broad range of generic drugs, Ionis specializes in RNA-targeted therapies, a niche but promising field. As we look to the future, the question remains: will Ionis's innovative approach close the gap?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025